Clinical Trial Update: Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis [Phase 3]

View source ↗

Summary

An extension study of etelcalcetide for secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis has completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Parsabiv (etelcalcetide)

Snippet

Sponsor: Amgen | Conditions: Hyperparathyroidism, Secondary | Phase 3 | Status: COMPLETED | Results posted: 2017-11-17